Changes in Haematological Indices, Blood Viscosity and Inhibitors of Coagulation during Treatment of Endometriosis with Danazol
article
OA: closed
CC0
⤵ 4 in-corpus citations
AI-generated summary
Danazol treatment for endometriosis significantly increased hemoglobin, red cell count, hematocrit, and platelet count while decreasing fibrinogen, increasing blood viscosity, and altering coagulation inhibitors and fibrinolytic activity.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The effects of treatment with danazol (600 mg daily) on haemostatic and haematological function were investigated in 18 pre-menopausal women with endometriosis. Blood samples were taken at 2 pre-treatment visits, at 6, 12 and 24 weeks on treatment, and at 6 weeks after discontinuation of the drug. Haemoglobin, red cell count, haematocrit and platelet count all rose significantly during treatment with danazol (p < 0.01 vs. baseline). Plasma fibrinogen levels fell significantly (p < 0.01), while whole blood viscosity increased during treatment and remained significantly elevated at follow-up. The prothrombin time shortened, but remained within normal limits, and there were no significant changes in factor VII:C, VIIa, or fibrinopeptide A. No significant changes were found in platelet function. Plasma B-beta 15-42 increased significantly. Functional levels of protein C, protein S, and antithrombin III, all rose significantly, above the normal range, while C4b-binding protein levels fell. We conclude that the observed changes in coagulation inhibitors and fibrinolytic activity may be considered beneficial in the context of venous thromboembolism. The rheological effects, however, indicate a degree of caution in the use of the drug in individuals considered to be at risk from arterial cardiovascular disease.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (4)
- Danazol for heavy menstrual bleeding 2007
- Matalliotakis IM, Goumenou AG, Koumantakis GE, Neonaki MA, Koumantakis EE, Dionyssopoulou E, Athanassakis I, Vassiliadis S. Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines [Int Immunopharmacol 2003; 3(1):81–89] 2003
- Danazol for heavy menstrual bleeding 2002
- Revealing the enigma of coagulation in endometriosis: the risk of thrombosis and the role of antithrombotic treatment 2020
Cited by (4)
- Revealing the enigma of coagulation in endometriosis: the risk of thrombosis and the role of antithrombotic treatment 2020
- Danazol for heavy menstrual bleeding 2007
- Matalliotakis IM, Goumenou AG, Koumantakis GE, Neonaki MA, Koumantakis EE, Dionyssopoulou E, Athanassakis I, Vassiliadis S. Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines [Int Immunopharmacol 2003; 3(1):81–89] 2003
- Danazol for heavy menstrual bleeding 2002
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:11:24.284338+00:00
License: CC0
· commercial use OK